Notify me when GMS Ventures & Investments files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| OTLK | Outlook Therapeutics, Inc. | Common Stock, par value $0.01 per share | 50.3% | $45.3M | $20.1M | 29M | +79.4% | GMS VENTURES & INVESTMENTS | May 27, 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Date Filed |
|---|